Tarsa plans 2011 oral calcitonin NDA
This article was originally published in Scrip
Executive Summary
Tarsa Therapeutics is hoping to submit an NDA to the US FDA later this year for its oral recombinant salmon calcitonin programme for the treatment and prevention of postmenopausal osteoporosis